Treatment with Nexviadyme^®

Nexviadyme^® (avalglucosidase alfa) is an enzyme replacement monotherapy (ERT) indicated for the long-term treatment of patients with Pompe disease (acid α-glucosidase deficiency), both infantile form (IOPD) and late form (LOPD).¹

COMET - The first pivotal, head-to-head, ERT clinical trial in LOPD²

COMET study: Nexviadyme^® (avalglucosidase alfa) helped patients improve their ability to breathe and walk compared with baseline.

Watch this short video and have a brief overview of the design and results of the study

Efficacy and Safety of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease After 97 Weeks A Phase 3 Randomized Clinical Trial³

Click the link below and get access to the COMET 97 week article for more information.

NEO-EXT study: Long term safety and efficacy evaluation of patients with LOPD - follow up 6,5y⁴

Watch this short video and have a brief overview of the design and results of the study.

Summary of Product Characteristics - Nexviadyme^® (avalglucosidase alfa)

Click the link below and get access to the Summary of Product Characteristics for more information on Nexviadyme^®.

Summary of Product Characteristics - Myozyme^® (alglucosidase alfa)

Click the link below and get access to the Summary of Product Characteristics for more information on Myozyme^®.